Research Progress on the Regulation of Bone Homeostasis by Oncostatin M

doi:10.13701/j.cnki.kqyxyj.2019.11.005

Abstract

Abstract: Bone tissue is in the dynamic equilibrium state of bone resorption and bone formation throughout life, namely bone homeostasis. In the body, a complex network of cells and cytokines regulates bone homeostasis. Oncostatin M (OSM), as a member of the IL-6 family, is a cytokine with multiple biological activities. Recent studies have shown that osteoblasts, osteocytes, and macrophages can regulate bone formation and bone resorption by secreting OSM, which plays an important role in bidirectional regulation of bone homeostasis. This paper reviews the research progress of OSM on bone homeostasis.

Key words: oncostatin M, bone homeostasis, osteoblast, osteoclast

FENG Lihua, XIA Haibin. Research Progress on the Regulation of Bone Homeostasis by Oncostatin M[J]. Journal of Oral Science Research, 2019, 35(11): 1026-1029.

References

[1] Ginaldi L, De Martinis M. Osteoimmunology and beyond [J]. Curr Med Chem, 2016, 23(33): 3754-3774.
[2] Tonna S, Sims NA. Talking among ourselves: paracrine control of bone formation within the osteoblast lineage [J]. Calcif Tissue Int, 2014, 94(1): 35-45.
[3] Sims NA. Cell-specific paracrine actions of IL-6 family cytokines from bone, marrow and muscle that control bone formation and resorption [J]. Int J Biochem Cell Biol, 2016, 79:14-23.
[4] Ryan RE, Martin B, Mellor L, et al. Oncostatin M binds to extracellular matrix in a bioactive conformation: Implications for inflammation and metastasis [J]. Cytokine, 2015, 72(1): 71-85.
[5] Sims NA, Quinn JM. Osteoimmunology: oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease [J]. Bonekey Rep, 2014, 3: 527.
[6] Richards CD. The enigmatic cytokine oncostatin M and roles in disease [J]. ISRN Inflamm, 2013, 2013: 512103.
[7] Zarling JM, Shoyab M, Marquardt H, et al. Oncostatin M: a growth regulator produced by differentiated histiocytic lymphoma cells [J]. Proc Natl Acad Sci U S A, 1986, 83(24):9739-9743.
[8] Hermanns HM. Oncostatin M and interleukin-31: Cytokines, receptors, signal transduction and physiology [J]. Cytokine Growth Factor Rev, 2015, 26(5): 545-558.
[9] de Hooge AS, van de Loo FA, Bennink MB, et al. Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-κB ligand [J]. Am J Pathol, 2002, 160(5):1733-1743.
[10] Moxham JP. Oncostatin-M enhances osteoinduction in a rabbit critical calvarial defect model [J]. Laryngoscope, 2007, 117(10):1790-1797.
[11] Walker EC, Johnson RW, Hu Y, et al. Murine oncostatin M acts via leukemia inhibitory factor receptor to phosphorylate signal transducer and activator of transcription 3 (STAT3) but not STAT1, an effect that protects bone mass [J]. J Biol Chem, 2016, 291(41): 21703-21716.
[12] Guihard P, Boutet M, Brounais-Le Royer B, et al. Oncostatin M, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury [J]. Am J Pathol, 2015, 185(3): 765-775.
[13] Sato F, Miyaoka Y, Miyajima A, et al. Oncostatin M maintains the hematopoietic microenvironment in the bone marrow by modulating adipogenesis and osteogenesis [J]. PLoS One, 2014, 9(12): e116209.
[14] Sims NA, Walsh NC. GP130 cytokines and bone remodelling in health and disease [J]. BMB Rep, 2010, 43(8):513-523.
[15] Johnson RW, Brennan HJ, Vrahnas C, et al. The primary function of gp130 signaling in osteoblasts is to maintain bone formation and strength, rather than promote osteoclast formation [J]. J Bone Miner Res, 2014, 29(6):1492-1505.
[16] Standal T, Johnson RW, Mcgregor NE, et al. gp130 in late osteoblasts and osteocytes is required for PTH-induced osteoblast differentiation [J]. J Endocrinol, 2014, 223(2): 181-190.
[17] Dey G, Radhakrishnan A, Syed N, et al. Signaling network of Oncostatin M pathway [J]. J Cell Commun Signal, 2013, 7(2):103-108.
[18] Miyaoka Y, Tanaka M, Naiki T, et al. Oncostatin M inhibits adipogenesis through the RAS/ERK and STAT5 signaling pathways [J]. J Biol Chem, 2006, 281(49): 37913-37920.
[19] Song HY, Jeon ES, Kim JI, et al. Oncostatin M promotes osteogenesis and suppresses adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells [J]. J Cell Biochem, 2007, 101(5): 1238-1251.
[20] Smyth DC, Takenaka S, Yeung C, et al. Oncostatin M regulates osteogenic differentiation of murine adipose-derived mesenchymal progenitor cells through a PKCdelta-dependent mechanism [J]. Cell Tissue Res, 2015, 360(2): 309-319.
[21] Zou F, Xu JC, Wu GH, et al. Effects of oncostatin M on cell proliferation and osteogenic differentiation in C3H10T1/2 [J]. J Musculoskelet Neuronal Interact, 2016, 16(4):377-385.
[22] Zhang Y, Böse T, Unger RE, et al. Macrophage type modulates osteogenic differentiation of adipose tissue MSCs [J]. Cell Tissue Res, 2017, 369(2):273-286.
[23] Guihard P, Danger Y, Brounais B, et al. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling [J]. Stem Cells, 2012, 30(4):762-772.
[24] Nicolaidou V, Wong MM, Redpath AN, et al. Monocytes induce STAT3 activation in human mesenchymal stem cells to promote osteoblast formation [J]. PLoS One, 2012, 7(7): e39871.
[25] Fernandes TJ, Hodge JM, Singh PP, et al. Cord blood-derived macrophage-lineage cells rapidly stimulate osteoblastic maturation in mesenchymal stem cells in a glycoprotein-130 dependent manner [J]. PLoS One, 2013, 8(9): e73266.
[26] Hirata E, Miyako E, Hanagata N, et al. Carbon nanohorns allow acceleration of osteoblast differentiation via macrophage activation [J]. Nanoscale, 2016, 8(30): 14514-14522.
[27] Ni J, Yuan XM, Yao Q, et al. OSM is overexpressed in knee osteoarthritis and Notch signaling is involved in the effects of OSM on MC3T3-E1 cell proliferation and differentiation [J]. Int J Mol Med, 2015, 35(6): 1755-1760.
[28] Zheng W, Guan J. Oncostatin M promotes the osteogenic differentiation of mouse MC3T3-E1 osteoblasts through the regulation of monocyte chemotactic protein-1 [J]. Mol Med Rep, 2018, 18(3): 2523-2530.
[29] Jay PR, Centrella M, Lorenzo J, et al. Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption [J]. Endocrinology, 1996, 137(4): 1151-1158.
[30] Hui W, Cawston TE, Richards CD, et al. A model of inflammatory arthritis highlights a role for oncostatin M in pro-inflammatory cytokine-induced bone destruction via RANK/RANKL [J]. Arthritis Res Ther, 2005, 7(1): R57-R64.
[31] Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis [J]. Endocrinology, 2005, 146(11): 4577-4583.
[32] Walker EC, Poulton IJ, Mcgregor NE, et al. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo [J]. J Bone Miner Res,2012,27(4):902-912.
[33] Walker EC, Johnson RW, Hu Y, et al. Murine oncostatin M acts via leukemia inhibitory factor receptor to phosphorylate signal transducer and activator of transcription 3 (STAT3) but not STAT1, an effect that protects bone mass [J]. J Biol Chem, 2016, 291(41): 21703-21716.